Three-year results of a multicenter prospective study of transoral incisionless fundoplication

Surgical Innovation

Volumn 20, Issue 4, 2013, Pages 321-330

  Muls, Vinciane ^a   Eckardt, Alexander J ^b   Marchese, Michele ^c   Bastens, Boris ^d   Buset, Michel ^a   Devière, Jacques ^e   Louis, Hubert ^e   Rajan, Amin ^f   Daniel, Michael A ^g   Costamagna, Guido ^c  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c CATHOLIC UNIVERSITY   (Italy)

^d Clinique Saint Joseph   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f Centre Hospitalier interregional Edith Cavell   (Belgium)

^g EndoGastric Solutions Inc   (United States)

Author keywords

EsophyX; fundoplication; gastroesophageal reflux; heartburn; hiatal hernia; TIF

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; DIGESTIVE SURGICAL EQUIPMENT; ESOPHAGUS PH; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; STOMACH FUNDOPLICATION; TRANSORAL INCISIONLESS FUNDOPLICATION; TREATMENT FAILURE;

ESOPHYX; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIATAL HERNIA; TIF;

ADULT; AGED; ESOPHAGEAL PH MONITORING; FEMALE; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84880271712     PISSN: 15533506     EISSN: 15533514     Source Type: Journal    
DOI: 10.1177/1553350612459275     Document Type: Article

References (29)

1. Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005 ; 18: 393-400
2. Brook RA, Wahlqvist P, Kleinman NL, et al. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther. 2007 ; 26: 889-898
3. Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008 ; 27: 249-256
4. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008 ; 179: 319-326
5. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006 ; 4: 597-604
6. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010 ; 153: 378-386
7. Lundell L. Surgery of gastroesophageal reflux disease: a competitive or complementary procedure?. Dig Dis. 2004 ; 22: 161-170
8. Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up. J Gastrointest Surg. 2006 ; 10: 1312-1316
9. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 2008 ; 57: 1207-1213
10. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs. esomprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011 ; 305: 1969-1977
11. Cadière GB, Rajan A, Germay O, Himpens J. Endoluminal fundoplication by a transoral device for the treatment of GERD: a feasibility study. Surg Endosc. 2008 ; 22: 332-342
12. Cadière GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication (TIF) using EsophyX. Surg Endosc. 2009 ; 23: 957-964
13. Demyttenaere SV, Bergman S, Pham T, et al. Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc. 2010 ; 24: 854-858
14. Bell RC, Freeman KD. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. Surg Endosc. 2011 ; 25: 1975-1984
15. Barnes WE, Hoddinott KM, Mundy S, Williams M. Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg Innov. 2011 ; 18: 119-129
16. Trad KS, Turgeon DG, Deljkich E. Long-term outcomes after transoral incisionless fundoplication in patients with GERD and LPR symptoms. Surg Endosc. 2012 ; 26: 650-660
17. Velanovich V. Endoscopic, endoluminal fundoplication for gastroesophageal reflux disease: initial experience and lessons learned. Surgery. 2010 ; 148: 646-651
18. Cadiere GB, Buset M, Muls V, et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg. 2008 ; 32: 1676-1688
19. Cadiere GB, Rajan A, Rqibate M, et al. Endoluminal fundoplication (ELF): evolution of EsophyX, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol. 2006 ; 15: 348-355
20. Velanovich V, Vallance SR, Gusz JR, et al. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg. 1996 ; 183: 217-222
21. Pleskow D, Rothstein R, Lo S, et al. Endoscopic full thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. Gastrointest Endosc. 2005 ; 61: 643-649
22. Rothstein R, Filipi C, Caca K, et al. Endoscopic full thickness plication for the treatment of gastroesophageal reflux disease: a randomized, sham-controlled trial. Gastroenterology. 2006 ; 131: 704-712
23. Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus. 2007 ; 20: 130-134
24. Tseng D, Rizvi AZ, Fennerty MB, et al. Forty-eight-hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastrointest Surg. 2005 ; 9: 1043-1051
25. Sarela AI, Hick DG, Verbeke CS, et al. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch Surg. 2004 ; 139: 547-551
26. Oritz A, Martinez de, Haro LF, Parrilla P, et al. 24-hours pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors. Br J Surg. 1999 ; 86: 1472-1474
27. Ouata-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998 ; 93: 711-716
28. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol. 1994 ; 89: 989-991
29. Testoni PA, Vailati C, Testoni S, Corsetti M. Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome. Surg Endosc. 2012 ; 26: 1425-1435